Mustafa Dinc
Research Subjects
Mustafa Dinc has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Sevket Balta
Department of Cardiology, Hayat Hospital, Malatya, Turkey
18 shared publications Aydogan Aydogdu
Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital - 06010, Etlik, Ankara, Turkey
12 shared publications- Coskun Meric
Department of Endocrinology and Metabolism, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, University of Health Sciences 06018 Ankara, Turkey
12 shared publications Omer Azal
Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital - 06010, Etlik, Ankara, Turkey
12 shared publications- Alper Sonmez
Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey
11 shared publications Mustafa Cakar
Gulhane Medical Academy, Turkey
10 shared publications
Latest Publications
- Open Access
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (1) , 30-36
Gender Differences in Cardiometabolic Risk Factors and Indicators of Aortic Stiffness in Individuals with Prediabetes
Objective: Cardiometabolic risk factors and biomarkers reflecting various pathophysiological pathways differ between men and women. In this study, gender differences were analyzed in some cardiometabolic risk indices and evaluated the indicators of arterial stiffness (AS) in men compared to women with prediabetes (preD) without cardiovascular disease. Methods: Data from 581 individuals (189 with normal plasma glucose and 392 with preD, aged 18-86 years) were analyzed cross-sectionally. The relationship between gender and different biomarkers was evaluated. Aortic stiffness index (ASI) was used to represent AS and was calculated as follows: ln [systolic blood pressure (SBP)/ diastolic blood pressure]/ [(ascending aorta systolic diameter − ascending aorta diastolic diameter (ADS)]/ADS. Multivariable linear regression was used to explore indicators of ASI. Results: Women with preD were older than men. The frequencies of comorbidities were significantly higher in preD men. Epicardial adipose tissue (EAT) (4.27 Å} 1.87 vs. 3.77 Å} 1.94), ASI (15.78 Å} 11.34 vs. 12.22 Å} 13.04), and lipid accumulation product index (LAPI) [59.98 (51.68) vs. 54.36 (57.04)] were significantly higher in preD men than in preD women. There was a significant correlation between ASI and age, body mass index (BMI), metabolic syndrome, waist circumference (WC), EAT, LAPI, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), insulin, creatinine, glomerular filtration rate (GFR), and SBP. In men, ASI was significantly correlated with age, MetS, BMI, WC, EAT, FPG, HOMA-IR, HbA1c, GFR, red blood cell distribution width, and SBP. Conclusion: These findings highlight that the development of AS in preD may be due to common and sex-specific risk factors.
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (1) , 30-36
Open AccessGender Differences in Cardiometabolic Risk Factors and Indicators of Aortic Stiffness in Individuals with Prediabetes
Objective: Cardiometabolic risk factors and biomarkers reflecting various pathophysiological pathways differ between men and women. In this study, gender differences were analyzed in some cardiometabolic risk indices and evaluated the indicators of arterial stiffness (AS) in men compared to women with prediabetes (preD) without cardiovascular disease. Methods: Data from 581 individuals (189 with normal plasma glucose and 392 with preD, aged 18-86 years) were analyzed cross-sectionally. The relationship between gender and different biomarkers was evaluated. Aortic stiffness index (ASI) was used to represent AS and was calculated as follows: ln [systolic blood pressure (SBP)/ diastolic blood pressure]/ [(ascending aorta systolic diameter − ascending aorta diastolic diameter (ADS)]/ADS. Multivariable linear regression was used to explore indicators of ASI. Results: Women with preD were older than men. The frequencies of comorbidities were significantly higher in preD men. Epicardial adipose tissue (EAT) (4.27 Å} 1.87 vs. 3.77 Å} 1.94), ASI (15.78 Å} 11.34 vs. 12.22 Å} 13.04), and lipid accumulation product index (LAPI) [59.98 (51.68) vs. 54.36 (57.04)] were significantly higher in preD men than in preD women. There was a significant correlation between ASI and age, body mass index (BMI), metabolic syndrome, waist circumference (WC), EAT, LAPI, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), insulin, creatinine, glomerular filtration rate (GFR), and SBP. In men, ASI was significantly correlated with age, MetS, BMI, WC, EAT, FPG, HOMA-IR, HbA1c, GFR, red blood cell distribution width, and SBP. Conclusion: These findings highlight that the development of AS in preD may be due to common and sex-specific risk factors.
- 1 December 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (4) , 355-362
Clinical Utility of Hepassocin and TXNDC5 in Patients with Non-alcoholic Fatty Liver Disease and/or Type 2 Diabetes
- 1 December 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (4) , 355-362
Clinical Utility of Hepassocin and TXNDC5 in Patients with Non-alcoholic Fatty Liver Disease and/or Type 2 Diabetes
- Open Access
- 12 July 2023
- Published by Mardin Artuklu University in Artuklu International Journal of Health Sciences
- Vol. 3 (2) , 129-136
Serum Myonectin and Adropin Levels in Predicting Diabetes
Introduction: Myonectin is a myokine associated with type 2 diabetes mellitus and insulin resistance, and adropin is a peptide hormone that prevents IR and impaired glucose tolerance. Adropin is produced by the liver and regulates energy homeostasis. This research aimed to examine the serum levels of myonectin and adropin levels among prediabetes, newly-diagnosed type 2 diabetes mellitus, and healthy controls. Methods: For this cross-sectional study, a total of 167 individuals were divided into 3 subgroups using OGTT and HbA1c; 61 prediabetes (36.5%), 62 nT2DM (37.1%), and 44 healthy controls (26.3%). Serum levels of myonectin and adropin were assayed using enzyme-linked immunoassay kits. The anthropometric (age, gender, weight, height, waist/hip ratio -WHR-, waist and hip circumference, and body mass index -BMI-) and biochemistry findings of the participants were evaluated between the groups. Results: Our study showed that myonectin levels are associated with nT2DM and WHR (p = 0.028 and p = 0.015, respectively). The serum levels of myonectin are significantly correlated with systolic blood pressure values in the prediabetes group (p = 0.017). Linear regression analysis revealed that nT2DM affects the serum levels of myonectin, but not adropin values. The adropin levels are correlated with LDL-cholesterol, total cholesterol, and triglyceride levels in the nT2DM group (p = 0.002, p= 0.004, and p = 0.035, respectively). Conclusion: The findings of the previous studies are supported by those of this study and indicated that the serum levels of myonectin may be associated with newly-diagnosed T2DM patients. Serum myonectin levels could be a valuable marker for predicting diabetes mellitus.
- 12 July 2023
- Published by Mardin Artuklu University in Artuklu International Journal of Health Sciences
- Vol. 3 (2) , 129-136
Open AccessSerum Myonectin and Adropin Levels in Predicting Diabetes
Introduction: Myonectin is a myokine associated with type 2 diabetes mellitus and insulin resistance, and adropin is a peptide hormone that prevents IR and impaired glucose tolerance. Adropin is produced by the liver and regulates energy homeostasis. This research aimed to examine the serum levels of myonectin and adropin levels among prediabetes, newly-diagnosed type 2 diabetes mellitus, and healthy controls. Methods: For this cross-sectional study, a total of 167 individuals were divided into 3 subgroups using OGTT and HbA1c; 61 prediabetes (36.5%), 62 nT2DM (37.1%), and 44 healthy controls (26.3%). Serum levels of myonectin and adropin were assayed using enzyme-linked immunoassay kits. The anthropometric (age, gender, weight, height, waist/hip ratio -WHR-, waist and hip circumference, and body mass index -BMI-) and biochemistry findings of the participants were evaluated between the groups. Results: Our study showed that myonectin levels are associated with nT2DM and WHR (p = 0.028 and p = 0.015, respectively). The serum levels of myonectin are significantly correlated with systolic blood pressure values in the prediabetes group (p = 0.017). Linear regression analysis revealed that nT2DM affects the serum levels of myonectin, but not adropin values. The adropin levels are correlated with LDL-cholesterol, total cholesterol, and triglyceride levels in the nT2DM group (p = 0.002, p= 0.004, and p = 0.035, respectively). Conclusion: The findings of the previous studies are supported by those of this study and indicated that the serum levels of myonectin may be associated with newly-diagnosed T2DM patients. Serum myonectin levels could be a valuable marker for predicting diabetes mellitus.
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 401-406
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome
Patients with Klinefelter Syndrome (KS) have increased cardiometabolic risk however the pathogenesis is not clear. We investigated the presence of endothelial dysfunction, insulin resistance and inflammation in an unconfounded population of KS. A total of 32 patients with KS (mean age 21.59 ± 1.66 years) and 33 healthy control subjects (mean age: 22.15 ± 1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA–IR) index and high–sensitivity C–reactive protein (hs–CRP) levels were measured. The patients had higher Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), insulin, HOMA–IR and ADMA levels (p < 0.001 for all) and lower High Density Lipoprotein Cholesterol (HDL–C) and total testosterone levels (p=0.002 and p<0.001, respectively), compared to the healthy controls. Total testosterone levels were significantly negatively correlated to ADMA (r = -0.479, p < 0,001), hs–CRP (r = -0.291, p = 0.034) and positively correlated to HDL–C (r = 0.429, p = 0.001) levels. The multivariate analysis has shown that total testosterone (β = -0.412, p = 0.001) and TG (β = 0.332, p = 0.009) levels were the significant independent determinants of the plasma ADMA levels. The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present. Also, hypogonadism seems to play an important role for increased cardiometabolic risk in patients with KS.
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 401-406
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome
Patients with Klinefelter Syndrome (KS) have increased cardiometabolic risk however the pathogenesis is not clear. We investigated the presence of endothelial dysfunction, insulin resistance and inflammation in an unconfounded population of KS. A total of 32 patients with KS (mean age 21.59 ± 1.66 years) and 33 healthy control subjects (mean age: 22.15 ± 1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA–IR) index and high–sensitivity C–reactive protein (hs–CRP) levels were measured. The patients had higher Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), insulin, HOMA–IR and ADMA levels (p < 0.001 for all) and lower High Density Lipoprotein Cholesterol (HDL–C) and total testosterone levels (p=0.002 and p<0.001, respectively), compared to the healthy controls. Total testosterone levels were significantly negatively correlated to ADMA (r = -0.479, p < 0,001), hs–CRP (r = -0.291, p = 0.034) and positively correlated to HDL–C (r = 0.429, p = 0.001) levels. The multivariate analysis has shown that total testosterone (β = -0.412, p = 0.001) and TG (β = 0.332, p = 0.009) levels were the significant independent determinants of the plasma ADMA levels. The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present. Also, hypogonadism seems to play an important role for increased cardiometabolic risk in patients with KS.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Hematological indices in congenital hypogonadism and the effect of testosterone replacement therapy: A retrospective study
Introduction: Patients with hypogonadism are at increased risk for cardiovascular diseases. Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) are hematological indices that are surrogate markers of adverse cardiovascular outcomes. This study investigated the platelet count, MPV levels, PLR, and NLR in patients with congenital hypogonadotrophic hypogonadism (CHH) and also studied the effect of testosterone replacement therapy (TRT) on these parameters. Methods: A total of 67 young male patients with CHH (mean age: 21.5±2.0 years) and 68 healthy control subjects (mean age: 21.9±1.3 years) were enrolled in the study. The demographic parameters, homeostatic model assessment-insulin resistance (HOMA-IR), platelet count, MPV, PLR, and NLR were measured in patients with CHH and healthy controls before and after TRT. Results: The patients had higher WC (P=0.04), triglycerides (P=0.02), insulin (PPP=0.001), MPV (P=0.004), and PLR (P=0.003) levels and lower FSH, LH, and total testosterone (PPP=0.001, PP=0.03, respectively) and decreased HDL-C levels (Pr=−0.23, P=0.009), MPV (r=−0.0.22, P=0.013), and PLR. (r=−0.0.22, P=0.014). Conclusion: The present study showed that platelet activation may play a pivotal role in the pathogenesis of cardiometabolic risk of patients with hypogonadism. Moreover, the short time TRT in treatment naïve young patients with CHH did not have any effect on the platelet count and size.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Hematological indices in congenital hypogonadism and the effect of testosterone replacement therapy: A retrospective study
Introduction: Patients with hypogonadism are at increased risk for cardiovascular diseases. Mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) are hematological indices that are surrogate markers of adverse cardiovascular outcomes. This study investigated the platelet count, MPV levels, PLR, and NLR in patients with congenital hypogonadotrophic hypogonadism (CHH) and also studied the effect of testosterone replacement therapy (TRT) on these parameters. Methods: A total of 67 young male patients with CHH (mean age: 21.5±2.0 years) and 68 healthy control subjects (mean age: 21.9±1.3 years) were enrolled in the study. The demographic parameters, homeostatic model assessment-insulin resistance (HOMA-IR), platelet count, MPV, PLR, and NLR were measured in patients with CHH and healthy controls before and after TRT. Results: The patients had higher WC (P=0.04), triglycerides (P=0.02), insulin (PPP=0.001), MPV (P=0.004), and PLR (P=0.003) levels and lower FSH, LH, and total testosterone (PPP=0.001, PP=0.03, respectively) and decreased HDL-C levels (Pr=−0.23, P=0.009), MPV (r=−0.0.22, P=0.013), and PLR. (r=−0.0.22, P=0.014). Conclusion: The present study showed that platelet activation may play a pivotal role in the pathogenesis of cardiometabolic risk of patients with hypogonadism. Moreover, the short time TRT in treatment naïve young patients with CHH did not have any effect on the platelet count and size.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Depression screening in adults with diabetes
Introduction: Elevated depressive symptoms and depressive disorders affect one in four patients with type 1 or type 2 diabetes (1). Thus, routine screening for depressive symptoms is indicated in this high-risk population. Current guidelines all recommend screening for depression in diabetic population(2). The Patient Health Questionnaire-9 (PHQ-9) is a valid screening tool for depression in individuals with diabetes (3). There is no specific data about the prevalence of depressive disorders diabetic population of Turkey. Therefore, we planned this study to investigate depressive disorder incidence in a small group of diabetic patient population. Methods: The demographic and laboratory parameters including glycated hemoglobin (HbA1c), lipid levels and body-mass indexes (BMI) were measured and PHQ-9 questionnaire was applied to all the diabetic patients admitted our endocrinology department and accepted to participate in the study. We used a cut-off point of 10 and above as high risk for depression in PHQ-9 questionnaire. Results: A total of 552 patients with diabetes (mean age 58.548±12.13) were enrolled in the study. Based on the predefined PHQ-9 cut-off value, 87 (16%) participants had depressive disorders. The patients with depressive disorders had worse HbA1c (7.91±2.05 vs. 8.52±2.44 in depression negative and positive groups, respectively; P=0.012), BMI (31.54±5.72 vs. 34.17±7.96 in depression negative and positive groups, respectively; P=0.005). Although statistically unimportant, LDL-C, non-HDL-C and FBG levels were also higher in the depressive disorder positive group. Patients of whom HbA1c was above target (uncontrolled diabetes) had higher PHQ-9 scores and there was a positive correlation detected between PHQ-9 score and HbA1c values (r=0.108, P=0.011). Conclusion: Depressive disorders prevalence is higher than expected in diabetic population. As recommended by guidelines every diabetic patient should be screened for depressive disorders periodically. PHQ-9 questionnaire is a practical and useful material for screening depressive disorders in diabetic patients.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Depression screening in adults with diabetes
Introduction: Elevated depressive symptoms and depressive disorders affect one in four patients with type 1 or type 2 diabetes (1). Thus, routine screening for depressive symptoms is indicated in this high-risk population. Current guidelines all recommend screening for depression in diabetic population(2). The Patient Health Questionnaire-9 (PHQ-9) is a valid screening tool for depression in individuals with diabetes (3). There is no specific data about the prevalence of depressive disorders diabetic population of Turkey. Therefore, we planned this study to investigate depressive disorder incidence in a small group of diabetic patient population. Methods: The demographic and laboratory parameters including glycated hemoglobin (HbA1c), lipid levels and body-mass indexes (BMI) were measured and PHQ-9 questionnaire was applied to all the diabetic patients admitted our endocrinology department and accepted to participate in the study. We used a cut-off point of 10 and above as high risk for depression in PHQ-9 questionnaire. Results: A total of 552 patients with diabetes (mean age 58.548±12.13) were enrolled in the study. Based on the predefined PHQ-9 cut-off value, 87 (16%) participants had depressive disorders. The patients with depressive disorders had worse HbA1c (7.91±2.05 vs. 8.52±2.44 in depression negative and positive groups, respectively; P=0.012), BMI (31.54±5.72 vs. 34.17±7.96 in depression negative and positive groups, respectively; P=0.005). Although statistically unimportant, LDL-C, non-HDL-C and FBG levels were also higher in the depressive disorder positive group. Patients of whom HbA1c was above target (uncontrolled diabetes) had higher PHQ-9 scores and there was a positive correlation detected between PHQ-9 score and HbA1c values (r=0.108, P=0.011). Conclusion: Depressive disorders prevalence is higher than expected in diabetic population. As recommended by guidelines every diabetic patient should be screened for depressive disorders periodically. PHQ-9 questionnaire is a practical and useful material for screening depressive disorders in diabetic patients.
- Open Access
- 1 June 2017
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 61 (3) , 282-287
Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism
Key words: Hypogonadism; cardiometabolic risk; visceral adiposity index; triglyceride/high-density lipoprotein cholesterol ratio
- 1 June 2017
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 61 (3) , 282-287
Open AccessVisceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism
Key words: Hypogonadism; cardiometabolic risk; visceral adiposity index; triglyceride/high-density lipoprotein cholesterol ratio
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Endothelial dysfunction, inflammation and insulin resistance in patients with Klinefelter Syndrome
Introduction: The prevalence of cardiometabolic disorders such as type 2 diabetes mellitus, dysipidemia and metabolic syndrome is increased in patients with Klinefelter syndrome (KS). The mechanism by which cardiometabolic risk increases in patients with KS remains to be completely elucidated. We investigated the presence of inflammation, insulin resistance and endothelial dysfunction in an unconfounded population of KS. Methods: A total of 31 patients with KS (mean age 21.59±1.66 years) and 33 healthy control subjects (mean age: 22.15±1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), high sensitive C reactive protein (hs-CRP) and homeostatic model assessment of insulin resistance (HOMA-IR) levels were measured in patients and controls. Results: The patients had higher insulin, HOMA-IR and ADMA levels (P< 0.001 for all) and lower HDL-C (P=0.002) and total testosterone (P< 0.001) levels, compared to the healthy controls. There were significant negative correlations between the total testosterone levels and ADMA (r=−0.479, P< 0,001), hsCRP (r=−0.291, P=0.034), and significant positive correlation with HDL-C (r=0.429, P=0.001) levels. The multivariate analysis has shown that total testosterone (β=−0.412, P=0.001) and TG (β=0.332, P=0.009) levels were the significant independent determinants of the plasma ADMA levels. Conclusion: The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Endothelial dysfunction, inflammation and insulin resistance in patients with Klinefelter Syndrome
Introduction: The prevalence of cardiometabolic disorders such as type 2 diabetes mellitus, dysipidemia and metabolic syndrome is increased in patients with Klinefelter syndrome (KS). The mechanism by which cardiometabolic risk increases in patients with KS remains to be completely elucidated. We investigated the presence of inflammation, insulin resistance and endothelial dysfunction in an unconfounded population of KS. Methods: A total of 31 patients with KS (mean age 21.59±1.66 years) and 33 healthy control subjects (mean age: 22.15±1.03 years) were enrolled. The demographic parameters, Asymmetric dimethylarginine (ADMA), high sensitive C reactive protein (hs-CRP) and homeostatic model assessment of insulin resistance (HOMA-IR) levels were measured in patients and controls. Results: The patients had higher insulin, HOMA-IR and ADMA levels (P< 0.001 for all) and lower HDL-C (P=0.002) and total testosterone (P< 0.001) levels, compared to the healthy controls. There were significant negative correlations between the total testosterone levels and ADMA (r=−0.479, P< 0,001), hsCRP (r=−0.291, P=0.034), and significant positive correlation with HDL-C (r=0.429, P=0.001) levels. The multivariate analysis has shown that total testosterone (β=−0.412, P=0.001) and TG (β=0.332, P=0.009) levels were the significant independent determinants of the plasma ADMA levels. Conclusion: The results of the present study show that endothelial dysfunction and insulin resistance are prevalent even in the very young subjects with KS, who have no metabolic or cardiac problems at present.
- 2 May 2017
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 27 (6) , 451-457
Oxidative stress status in congenital hypogonadism: an appraisal
Patients with hypogonadism are at increased risk of cardiac and metabolic diseases. However, the pathogenesis of increased cardiometabolic risk in patients with hypogonadism is not clear. Oxidative stress plays an important role in the pathogenesis of cardiometabolic diseases. This study aimed to investigate possible differences in oxidative stress conditions between patients with hypogonadism and healthy controls. In this study, 38 male patients with congenital hypogonadotropic hypogonadism (CHH) (mean age: 21.7 ± 1.6 years) and 44 healthy male controls (mean age: 22.3 ± 1.4 years) with almost equal body mass index were enrolled. The demographic parameters, follicle-stimulating hormone (FSH), luteinizing hormone (LH), total and free testosterone, homeostatic model assessment of insulin resistance (HOMA-IR) and oxidative stress parameters, such as superoxide dismutase, catalase (CAT), glutathione peroxidase (GPx) and malondialdehyde (MDA), were compared between both groups. Compared to the healthy controls, triglycerides (p = .02), insulin levels, HOMA-IR values, CAT activities and MDA levels (p < .001 for all) were significantly higher and HDL cholesterol (p = .04), total and free testosterone, FSH, LH levels and GPx activity were significantly lower (p < .001 for all) in patients with CHH. There were significant correlations between total testosterone levels and CAT activity (r = −.33 p = .01), GPx activity (r = .36 p = .007) and MDA (r = −.47 p < .001) levels. The results of this study showed that young and treatment-naïve patients with congenital hypogonadism had an increased status of oxidative stress.
- 2 May 2017
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 27 (6) , 451-457
Oxidative stress status in congenital hypogonadism: an appraisal
Patients with hypogonadism are at increased risk of cardiac and metabolic diseases. However, the pathogenesis of increased cardiometabolic risk in patients with hypogonadism is not clear. Oxidative stress plays an important role in the pathogenesis of cardiometabolic diseases. This study aimed to investigate possible differences in oxidative stress conditions between patients with hypogonadism and healthy controls. In this study, 38 male patients with congenital hypogonadotropic hypogonadism (CHH) (mean age: 21.7 ± 1.6 years) and 44 healthy male controls (mean age: 22.3 ± 1.4 years) with almost equal body mass index were enrolled. The demographic parameters, follicle-stimulating hormone (FSH), luteinizing hormone (LH), total and free testosterone, homeostatic model assessment of insulin resistance (HOMA-IR) and oxidative stress parameters, such as superoxide dismutase, catalase (CAT), glutathione peroxidase (GPx) and malondialdehyde (MDA), were compared between both groups. Compared to the healthy controls, triglycerides (p = .02), insulin levels, HOMA-IR values, CAT activities and MDA levels (p < .001 for all) were significantly higher and HDL cholesterol (p = .04), total and free testosterone, FSH, LH levels and GPx activity were significantly lower (p < .001 for all) in patients with CHH. There were significant correlations between total testosterone levels and CAT activity (r = −.33 p = .01), GPx activity (r = .36 p = .007) and MDA (r = −.47 p < .001) levels. The results of this study showed that young and treatment-naïve patients with congenital hypogonadism had an increased status of oxidative stress.
- 15 February 2017
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 125 (04) , 256-261
Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens
Background: Intensive insulin treatment is bothersome in obese patients with type 2 diabetes mellitus. High insulin dosages further increase weight gain and the risk of hypoglycemia. Glucagon like peptide-1 receptor agonists decrease the insulin need, cause weight loss and reduce the risk of hypoglycemia. There is limited data about the effect of exenatide on obese diabetics under intensive insulin regimens. Methods: This retrospective case series report the clinical outcomes of 23 obese (13 morbidly obese) patients with uncontrolled type 2 diabetes mellitus (Age=59±10.44 years, body mass index 41.1±6.8 kg/m2, HbA1c 9.9±1.5%), under high dose (94.1±39.6 unit) intensive insulin. Exenatide twice daily was added for a mean follow-up period of 11.22±7.01 (3–30) months. Intensive insulin regimens were continued in 7 patients while the others were switched to basal insulin during the follow-up. Results: During the follow-up, mean HbA1c levels of the patients significantly improved (p=0.019), along with the significant decrease in body mass index and the total insulin need (p<0.001 for both). Baseline insulin dosages were significantly higher in the intensive regimen group (p=0.013) while other demographical and clinical characteristics were similar. No significant difference was present between the groups regarding the alterations of HbA1c, body mass index and the reduction in total insulin dosages. Conclusion: Add on exenatide appears to be a rational treatment modality in uncontrolled obese patients with type 2 diabetes mellitus despite intensive insulin regimens. Further prospective randomized studies with longer follow-up periods are recommended.
- 15 February 2017
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 125 (04) , 256-261
Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens
Background: Intensive insulin treatment is bothersome in obese patients with type 2 diabetes mellitus. High insulin dosages further increase weight gain and the risk of hypoglycemia. Glucagon like peptide-1 receptor agonists decrease the insulin need, cause weight loss and reduce the risk of hypoglycemia. There is limited data about the effect of exenatide on obese diabetics under intensive insulin regimens. Methods: This retrospective case series report the clinical outcomes of 23 obese (13 morbidly obese) patients with uncontrolled type 2 diabetes mellitus (Age=59±10.44 years, body mass index 41.1±6.8 kg/m2, HbA1c 9.9±1.5%), under high dose (94.1±39.6 unit) intensive insulin. Exenatide twice daily was added for a mean follow-up period of 11.22±7.01 (3–30) months. Intensive insulin regimens were continued in 7 patients while the others were switched to basal insulin during the follow-up. Results: During the follow-up, mean HbA1c levels of the patients significantly improved (p=0.019), along with the significant decrease in body mass index and the total insulin need (p<0.001 for both). Baseline insulin dosages were significantly higher in the intensive regimen group (p=0.013) while other demographical and clinical characteristics were similar. No significant difference was present between the groups regarding the alterations of HbA1c, body mass index and the reduction in total insulin dosages. Conclusion: Add on exenatide appears to be a rational treatment modality in uncontrolled obese patients with type 2 diabetes mellitus despite intensive insulin regimens. Further prospective randomized studies with longer follow-up periods are recommended.